rilvegostomig
astrazeneca
Not Tagged
$azn tigit x pd-1 bsab #rilvegostomig fails to impress in cpi refractory nsclc pts (orr: 3.9%), once again raising questions on potential of tigit as a target in lung cancer; az plans pivotal ph3 trial initiation in 2023 in undisclosed indication. #asco23 #asco2023 #cancer 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.